A detailed history of Twin Tree Management, LP transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Twin Tree Management, LP holds 95,600 shares of IONS stock, worth $3.32 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
95,600
Previous 10,381 820.91%
Holding current value
$3.32 Million
Previous $494,000 675.1%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$40.06 - $51.86 $82,002 - $106,157
2,047 Added 19.72%
12,428 $497,000
Q2 2024

Aug 13, 2024

BUY
$36.45 - $47.7 $102,716 - $134,418
2,818 Added 37.26%
10,381 $494,000
Q1 2024

May 09, 2024

BUY
$42.03 - $53.55 $317,872 - $404,998
7,563 New
7,563 $327,000
Q3 2023

Nov 14, 2023

BUY
$38.5 - $47.13 $786,978 - $963,384
20,441 New
20,441 $927,000
Q3 2022

Nov 10, 2022

BUY
$36.54 - $48.66 $859,311 - $1.14 Million
23,517 New
23,517 $1.04 Million
Q3 2021

Nov 12, 2021

SELL
$33.54 - $40.55 $985,472 - $1.19 Million
-29,382 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$34.54 - $47.25 $994,302 - $1.36 Million
28,787 Added 4838.15%
29,382 $1.17 Million
Q1 2020

May 13, 2020

BUY
$41.6 - $63.4 $10,982 - $16,737
264 Added 79.76%
595 $28,000
Q4 2019

Feb 14, 2020

SELL
$53.85 - $65.27 $11,146 - $13,510
-207 Reduced 38.48%
331 $20,000
Q3 2019

Nov 12, 2019

BUY
$59.06 - $72.15 $23,564 - $28,787
399 Added 287.05%
538 $32,000
Q2 2019

Aug 12, 2019

SELL
$62.09 - $86.14 $973,819 - $1.35 Million
-15,684 Reduced 99.12%
139 $9,000
Q4 2018

Feb 13, 2019

BUY
$43.37 - $59.54 $261,130 - $358,490
6,021 Added 61.43%
15,823 $855,000
Q3 2018

Nov 09, 2018

BUY
$42.88 - $53.7 $112,688 - $141,123
2,628 Added 36.63%
9,802 $506,000
Q2 2018

Aug 08, 2018

BUY
$40.53 - $50.7 $290,762 - $363,721
7,174 New
7,174 $299,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $4.93B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.